Ocular hypotensive agents
AssigneeR-Tech Ueno, Ltd.
InventorsRyuzo Ueno, Ryuiji Ueno
Life of this patent
Estimating the term…
Abstract
The present invention relates to ocular hypotensive agents which contains 13,14-dihydro-15-keto-prostagrandins, which shows no transient ocular hypertensive response that PGs usually show.
Claims26
A topical ocular composition comprising an amount effective as an ocular hypotensive agent of a 13,14-dihydro-15-keto-prostaglandin represented by the following formula (I):
- ##STR16## wherein A is ##STR17## wherein R is hydroxy, hydroxy C.sub.1-3 alkyl or C.sub.1-2 alkyl;
- Y is a saturated or unsaturated C.sub.2-6 hydrocarbon chain which is unsubstituted or substituted by oxo, halogen, an alkyl group or hydroxyl;
- Z is a C.sub.1-10 saturated or unsaturated hydrocarbon forming a straight-chain, a branched-chain or a ring, which is unsubstituted or substituted by halogen, an alkyl group, an alkoxy group, hydroxyl, a phenyl group or a phenoxy group;
- or the physiologically acceptable salts and carboxylic acid esters of the compounds of formula (I) said ester being a straight or branched-chain alkyl containing up to one unsaturated bond, cycloalkyl, benzyl, phenyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl or tetrahydropyranyl ester, of a compound of Formula (I);
- and a pharmaceutically acceptable carrier.
A method for treating ocular hypertension in a human patient needing such treating which comprises administering to said patient an amount of a 13,14-dihydro-15-keto-prostaglandin of the formula (I) effective to treat ocular hypertension ##STR18## wherein A is ##STR19## wherein R is hydroxy, hydroxy C.sub.1-3 alkyl or C.sub.1-2 alkyl;
- Y is a saturated or unsaturated C.sub.2-6 hydrocarbon chain which is unsubstituted or substituted by oxo, halogen, an alkyl group or hydroxyl;
- Z is a C.sub.1-10 saturated or unsaturated hydrocarbon forming a straight-chain, a branched-chain or a ring, which is unsubstituted or substituted by halogen, an alkyl group, an alkoxy group, hydroxyl, a phenyl group or a phenoxy group;
- or the physiologically acceptable salts and carboxylic acid esters of the compounds of formula (I) said ester being a straight or branched-chain alkyl containing up to one unsaturated bond, cycloalkyl, benzyl, phenyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl or tetrahydropyranyl ester, of a compound of Formula (I).
A method for treating glaucoma in a human patient needing such treatment which comprises administering to said patient an amount of a 13,14-dihydro-15-keto-prostaglandin of the following formula (I) effective to treat glaucoma ##STR20## wherein A is ##STR21## wherein R is hydroxy, hydroxy C.sub.1-3 alkyl of C.sub.1-2 alkyl;
- Y is a saturated or unsaturated C.sub.2-6 hydrocarbon chain which is unsubstituted or substituted by oxo, halogen, an alkyl group or hydroxyl;
- Z is a C.sub.1-10 saturated or unsaturated hydrocarbon forming a straight-chain, a branched-chain or a ring, which is unsubstituted or substituted by halogen, an alkyl group, an alkoxy group, hydroxyl, a phenyl group or a phenoxy group;
- or the physiologically acceptable salts and carboxylic acid esters of the compounds of formula (I) said ester being a straight or branched-chain alkyl containing up to one unsaturated bond, cycloalkyl, benzyl, phenyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl or tetrahydropyranyl ester, a the compound of Formula (I).
The method of any of claims 4 or 12-19, wherein said administration is topically to the eye.
Dependencies are inferred from the claim text.